clinical trial · NCT04924114
A Study of MK-6194 (PT101) in Participants With Active Ulcerative Colitis (UC) (MK-6194-002)
Merck Sharp & Dohme LLC·phase1·completed·n = 57
Ulcerative ColitisMK-6194MK-6194-matching placebo
brief summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of MK-6194 in participants with active UC.
started
Oct 14, 2021
primary completion
Jan 8, 2024
completion
Jul 15, 2024
last updated
Aug 29, 2025
official title
A Phase 1b, Randomized, Adaptive, Double-Blind, Placebo-Controlled, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of PT101 in Subjects With Active Ulcerative Colitis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol